Cara Therapeutics Inc (NASDAQ:CARA) Expected to Announce Earnings of -$0.59 Per Share

Share on StockTwits

Wall Street brokerages forecast that Cara Therapeutics Inc (NASDAQ:CARA) will announce earnings per share (EPS) of ($0.59) for the current quarter, Zacks reports. Five analysts have made estimates for Cara Therapeutics’ earnings. The lowest EPS estimate is ($0.72) and the highest is ($0.49). Cara Therapeutics reported earnings of ($0.51) per share during the same quarter last year, which would indicate a negative year over year growth rate of 15.7%. The firm is expected to announce its next earnings results on Tuesday, November 5th.

According to Zacks, analysts expect that Cara Therapeutics will report full-year earnings of ($2.32) per share for the current year, with EPS estimates ranging from ($2.57) to ($2.08). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.11) per share, with EPS estimates ranging from ($3.01) to ($1.09). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Cara Therapeutics.

Cara Therapeutics (NASDAQ:CARA) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.03. Cara Therapeutics had a negative net margin of 420.97% and a negative return on equity of 68.36%. The firm had revenue of $5.21 million for the quarter, compared to analyst estimates of $5.14 million.

A number of brokerages have commented on CARA. BidaskClub upgraded shares of Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Needham & Company LLC upped their target price on shares of Cara Therapeutics from $28.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, May 29th. Piper Jaffray Companies upped their target price on shares of Cara Therapeutics from $35.00 to $39.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. Zacks Investment Research lowered shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, August 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective (down previously from $31.00) on shares of Cara Therapeutics in a research report on Monday, August 12th. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Cara Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $26.94.

In other news, CEO Derek T. Chalmers sold 5,528 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $21.42, for a total value of $118,409.76. Following the completion of the sale, the chief executive officer now directly owns 963,996 shares of the company’s stock, valued at approximately $20,648,794.32. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Mani Mohindru sold 37,431 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $25.00, for a total transaction of $935,775.00. Following the completion of the sale, the chief financial officer now directly owns 51,294 shares of the company’s stock, valued at $1,282,350. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 120,848 shares of company stock valued at $2,844,442. Company insiders own 5.80% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in CARA. TCG Advisors LP acquired a new stake in Cara Therapeutics during the first quarter valued at approximately $30,000. Aperio Group LLC acquired a new stake in Cara Therapeutics during the second quarter valued at approximately $88,000. BNP Paribas Arbitrage SA lifted its stake in Cara Therapeutics by 67,680.0% during the first quarter. BNP Paribas Arbitrage SA now owns 6,778 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 6,768 shares during the last quarter. Knott David M acquired a new stake in Cara Therapeutics during the first quarter valued at approximately $140,000. Finally, Sfmg LLC acquired a new stake in Cara Therapeutics during the second quarter valued at approximately $200,000. 58.03% of the stock is owned by institutional investors and hedge funds.

Shares of CARA stock opened at $22.93 on Friday. Cara Therapeutics has a 12 month low of $12.19 and a 12 month high of $27.55. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.04. The company’s fifty day moving average price is $23.61 and its two-hundred day moving average price is $20.00.

About Cara Therapeutics

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

See Also: What does it mean to hold a stock in street name?

Get a free copy of the Zacks research report on Cara Therapeutics (CARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MARK.SPACE  Market Cap Reaches $1.37 Million
MARK.SPACE Market Cap Reaches $1.37 Million
Naka Bodhi Token  Achieves Market Capitalization of $932,917.00
Naka Bodhi Token Achieves Market Capitalization of $932,917.00
VULCANO  Trading Up 1.2% Over Last Week
VULCANO Trading Up 1.2% Over Last Week
Surge Energy Inc  Given Consensus Recommendation of “Buy” by Analysts
Surge Energy Inc Given Consensus Recommendation of “Buy” by Analysts
-$0.54 Earnings Per Share Expected for Epizyme Inc  This Quarter
-$0.54 Earnings Per Share Expected for Epizyme Inc This Quarter
Peel Hunt Reaffirms Buy Rating for IQE
Peel Hunt Reaffirms Buy Rating for IQE


© 2006-2019 Ticker Report